Yearly Archives: 2018

­

Quark Pharmaceuticals Announces Acceptance of Presentation and Abstracts at ASN 2018 (October 23-28, 2018) and AAO 2018 (October 27-30, 2018) Annual Meetings

October 22nd, 2018|

FREMONT, Calif., Oct. 22, 2018 — Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based therapeutics for unmet medical needs, today announced the acceptance of several abstracts on two major products, teprasiran (previously known as QPI-1002) and QPI-1007.

Teprasiran, an siRNA targeting the p53 gene, is under […]

Quark Pharmaceuticals, Inc Announces First Patient Dosed in Phase 3 Clinical Trial of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery

July 9th, 2018|

Quark reached agreement with FDA on the overall Phase 3 trial design with a new innovative primary endpoint
Fremont, CA –  July 9, 2018 – Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based therapeutics for unmet medical needs, today announced the first patient dosed in the […]